Supported by

Stents, scaffolds and DCB

Find all the latest content on stents and scaffolds published on this website.

Since 1986, when the first cardiovascular stent was implanted, the development of drug-eluting stents (DES) and the recent introduction of bioresorbable scaffolds have revolutionised interventional cardiology. Keep up-to-date with the latest research; evolving tools, devices and techniques; the role of adjunctive pharmacotherapy; advances in imaging techniques as well as the use of invasive imaging and functional assessment. Find out more…

Filtered By
Stents, scaffolds and DCB

440 results

Sirolimus coated balloon for coronary artery disease and peripheral artery disease treatment: the new frontier

20 May 2025 – From EuroPCR 2025

This EuroPCR 2025 session delivers a comprehensive update on the MagicTouch sirolimus-coated balloon (SCB) and its expanding role in treating both coronary and peripheral artery disease (CAD/PAD). The session covers the extensive clinical trial program supporting MagicTouch as a versatile treatment option across multiple indications. It...

Sirolimus coated balloon for coronary artery disease and peripheral artery disease treatment: the new frontier

Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE

20 May 2025 – From EuroPCR 2025

Discover the latest evidence on the Supraflex thin-strut sirolimus DES in complex cases—from small vessels and diabetes to STEMI—supported by OCT analysis. This session highlights Supraflex’s performance in high bleeding risk and elderly patients, featuring data from FIRE, COMPARE, EARTH HBR, and Cruz Senior studies. Get...

Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE

The future is now: QFR and RMS to optimise coronary artery disease patient management

20 May 2025 – From EuroPCR 2025

See how next-generation technologies are reshaping coronary artery disease treatment in this EuroPCR 2025 session. Learn how QFR is being used to plan PCI and evaluate results, and discover new insights into RMS technology—offering a potential leap beyond traditional drug-eluting stents. From practical case experience to...

The future is now: QFR and RMS to optimise coronary artery disease patient management

Intracoronary value for PCI optimisation

20 May 2025 – From EuroPCR 2025

Optimize your PCI strategies with intracoronary insights in this session highlighting plaque stabilization, coronary stent optimization under pressure, and the critical role of intravascular imaging beyond angiography. Learn management approaches for traumatic coronary artery dissection and explore diagnosis of delayed stent fracture using enhanced stent visualization...

Intracoronary value for PCI optimisation

PCR's Got Talent Round 1 - Session 2

20 May 2025 – From EuroPCR 2025

Join the dynamic PCR's Got Talent Round 1 - Session 2 featuring cutting-edge research and innovations in interventional cardiology. Highlights include complex CTO PCI strategies, valve comparisons in TAVI for small annuli, PFO closure outcomes, long-term PCI durability, CT-guided robotic PCI, pacemaker prediction post-TAVI, and much...

PCR's Got Talent Round 1 - Session 2

DCB-PCI in de novo lesions

20 May 2025 – From EuroPCR 2025

Evaluate the role of drug-coated balloon (DCB) angioplasty in de novo coronary lesions with a focus on vessel diameter effects, comparisons to drug-eluting stents for small non-complex lesions, management of unstented dissections, high bleeding risk scenarios, and optimal dual antiplatelet therapy durations.

DCB-PCI in de novo lesions

New solutions for old problems

19 May 2025 – From EuroPCR 2025

Discover new solutions addressing persistent cardiovascular challenges, including novel diagnostic systems, vascular closure devices, specialized transcatheter closure technologies, and innovative stent-graft systems.

New solutions for old problems

Advances in the development of drug-coated balloon

22 May 2025 – From EuroPCR 2025

Join Florim Cuculi and Rony Mathew at this EuroPCR 2025 roundtable to assess the evolution of drug-coated balloons (DCBs) and their role in daily practice.

DCBs offer a compelling alternative to stent implantation in selected cases. However, they are not interchangeable—each is built using different drugs, carriers,...

Advances in the development of drug-coated balloon

Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome

21 May 2025 – From EuroPCR 2025

In this EuroPCR 2025 interview, Davide Capodanno and Woong Chol Kang discuss antithrombotic therapy in patients with acute coronary syndromes, focusing on the design and outcomes of the 4D-ACS trial. They describe the patient population enrolled in the study and introduce the two de-escalation strategies investigated:...

Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after DCS insertion in ACS

What are the essentials of the provisional strategy for non-left main true bifurcation lesions?

21 May 2025 – From EuroPCR 2025

Giuseppe Di Gioia and Jens Flensted Lassen explore the essentials of the provisional stenting strategy for non-left main true bifurcation lesions. This stepwise approach offers simplicity while preserving flexibility: start with one stent in the main vessel, and keep the option open for a second if...

What are the essentials of the provisional strategy for non-left main true bifurcation lesions?